MedTrace Logo

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

Conditions

Interventions

DRUG

PIPE-791 Dose B

Subjects will receive a daily oral dose of PIPE-791 in tablet form

DRUG

Placebo

Subjects will receive a daily oral dose of matching Placebo in tablet form

DRUG

PIPE-791 Dose A

Subjects will receive a daily oral dose of PIPE-791 in tablet form

Sponsors & Collaborators

  • Contineum Therapeutics

    lead INDUSTRY

Principal Investigators

  • Mudiaga O Sowho, MD, MPH · Contineum Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-08
Primary Completion
2028-05-31
Completion
2028-06-30
FDA Drug
Yes

Countries

  • Australia
  • Canada
  • Israel
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284459 on ClinicalTrials.gov